KalVista Pharmaceuticals, Inc. (FRA:4XC1)
Germany
· Delayed Price · Currency is EUR 11.40
-0.30 (-2.56%)
At close: Dec 3, 2025
KalVista Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | 2020 - 2016 |
| Revenue | 1.43 | - | - | - | - | - | Upgrade
|
| Cost of Revenue | 60.85 | 71.71 | 86.17 | 80.28 | 70.17 | 41.29 | Upgrade
|
| Gross Profit | -59.42 | -71.71 | -86.17 | -80.28 | -70.17 | -41.29 | Upgrade
|
| Selling, General & Admin | 143.37 | 116.29 | 54.28 | 30.6 | 26.45 | 16.64 | Upgrade
|
| Operating Expenses | 143.37 | 116.29 | 54.28 | 30.6 | 26.45 | 16.64 | Upgrade
|
| Operating Income | -202.79 | -188 | -140.45 | -110.87 | -96.61 | -57.92 | Upgrade
|
| Interest Expense | -9.31 | -5.79 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 6.59 | 6.44 | 3.9 | 2.23 | 1.09 | 0.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.89 | 2.48 | 0.14 | 0.09 | -1.54 | 0.85 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.23 | 3.25 | 8.44 | 15.78 | 15.3 | 9.93 | Upgrade
|
| EBT Excluding Unusual Items | -199.38 | -181.61 | -127.97 | -92.77 | -81.76 | -46.24 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.83 | 1.56 | 1.33 | -0.14 | -0.58 | - | Upgrade
|
| Pretax Income | -197.55 | -180.05 | -126.64 | -92.91 | -82.34 | -46.24 | Upgrade
|
| Income Tax Expense | 5.55 | 3.39 | - | - | - | - | Upgrade
|
| Net Income | -203.1 | -183.44 | -126.64 | -92.91 | -82.34 | -46.24 | Upgrade
|
| Net Income to Common | -203.1 | -183.44 | -126.64 | -92.91 | -82.34 | -46.24 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 50 | 37 | 28 | 24 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 50 | 37 | 28 | 24 | 19 | Upgrade
|
| Shares Change (YoY) | 29.51% | 34.98% | 31.89% | 13.96% | 28.17% | 7.58% | Upgrade
|
| EPS (Basic) | -3.95 | -3.69 | -3.44 | -3.33 | -3.36 | -2.42 | Upgrade
|
| EPS (Diluted) | -3.95 | -3.69 | -3.44 | -3.33 | -3.36 | -2.42 | Upgrade
|
| Free Cash Flow | -167.89 | -153.34 | -89.27 | -76.46 | -79.07 | -30.25 | Upgrade
|
| Free Cash Flow Per Share | -3.26 | -3.09 | -2.43 | -2.74 | -3.23 | -1.58 | Upgrade
|
| Operating Margin | -14220.83% | - | - | - | - | - | Upgrade
|
| Profit Margin | -14242.43% | - | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -11773.63% | - | - | - | - | - | Upgrade
|
| EBITDA | -201.82 | -187.05 | -139.63 | -110.15 | -96.05 | -57.39 | Upgrade
|
| D&A For EBITDA | 0.97 | 0.94 | 0.82 | 0.72 | 0.56 | 0.54 | Upgrade
|
| EBIT | -202.79 | -188 | -140.45 | -110.87 | -96.61 | -57.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.